N/A
Loading page data
Please wait a moment
Loading page data
Please wait a moment
Second Floor, 150 Fleet Street,
London, EC4A 2DQ.
+44 203-837-5656
108 W 39th Street, Ste 1006,
PMB2219, New York, NY 10018
+1 646-878-6329
IT Unit No. 504, 5th Floor, Icon
Tower, Baner, Pune - 411045.
+91 906 779 3500
In the past years, it has been observed that, there are many kinds of drug-eluting stents available in the market, which has strongly developed coronary artery disease (CAD) revascularization. This is majorly due to the declining rate of target lesion revascularization (TLR) and major adverse cardiac events (MACE).
Permanent drug-eluting stents coated with anti-proliferative agents reduce the incidence of restenosis and target lesion revascularization by inhibition of neointimal hyperplasia.
Permanent drug-eluting stents with permanent polymers do not degrade in vivo, and may raise the probability of polymer hypersensitivity or stent-related delayed arterial healing. Permanent drug-eluting stents have a lower rate of clinical trials due to the introduction of next-generation drug-eluting stents.
Next-generation drug-eluting stents are a modification of previous developed permanent drug-eluting stents, which offer enhanced drug delivery and stent flexibility. Permanent drug-eluting stents generally consist of three components; mainly a permanent metallic scaffold, an antiproliferative drug, and the polymer.
The increasing geriatric population is considered as the primary factor in driving the growth of the global permanent drug-eluting stents market. This is due to the high risk of developing arterial disorders in the geriatric population on a global level. Moreover, the rising prevalence of obesity and unhealthy lifestyle related to atherosclerosis are also major factors responsible for the growth of the global permanent drug-eluting stents market.
Furthermore, rising healthcare expenditure and increasing awareness in low middle-income countries are also some of the factors which are responsible for driving the growth of the global permanent drug-eluting stents market.
In addition, rising government support and growing research and development activities are also boosting the growth of the permanent drug-eluting stents market. However, the availability of alternative therapies is considered as a major obstacle hampering the growth of the global permanent drug-eluting stents market.
Furthermore, the increasing inclination of patients for drugs over surgical procedures is also limiting the growth of the global permanent drug-eluting stents market.
